Results 281 to 290 of about 4,684,794 (400)

Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki   +13 more
wiley   +1 more source

Feasibility and Safety of Transfemoral Aortic Valve Replacement Using Local Anesthesia in the Catheterization Suite Versus General Anesthesia in the Operation Theater

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background For over a decade, transfemoral transcatheter aortic valve replacements (TF‐TAVR) have been performed at the University Hospital of Nancy. A minimalistic approach to TF‐TAVR, conducted without general anesthesia and entirely percutaneously in a catheterization suite (simplified approach), has been reported to be as safe and ...
Guillaume Abadié   +8 more
wiley   +1 more source

Patients’ Preferences in Anticoagulant Therapy: Discrete Choice Experiment

open access: yesCirculation. Cardiovascular Quality and Outcomes, 2014
M. Najafzadeh   +5 more
semanticscholar   +1 more source

Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site‐specific thrombotic risk.
Stefan Verheye   +19 more
wiley   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu   +21 more
wiley   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier   +20 more
wiley   +1 more source

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies ...
Gerald Chun‐To So   +7 more
wiley   +1 more source

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy